IL231666B - Use of non-subtype b gag proteins for lentiviral packaging - Google Patents

Use of non-subtype b gag proteins for lentiviral packaging

Info

Publication number
IL231666B
IL231666B IL231666A IL23166614A IL231666B IL 231666 B IL231666 B IL 231666B IL 231666 A IL231666 A IL 231666A IL 23166614 A IL23166614 A IL 23166614A IL 231666 B IL231666 B IL 231666B
Authority
IL
Israel
Prior art keywords
subtype
gag proteins
lentiviral packaging
lentiviral
gag
Prior art date
Application number
IL231666A
Other languages
English (en)
Hebrew (he)
Other versions
IL231666A0 (en
Original Assignee
Pasteur Institut
Theravectys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47522726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL231666(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Theravectys filed Critical Pasteur Institut
Publication of IL231666A0 publication Critical patent/IL231666A0/en
Publication of IL231666B publication Critical patent/IL231666B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16051Methods of production or purification of viral material
    • C12N2740/16052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL231666A 2011-09-26 2014-03-23 Use of non-subtype b gag proteins for lentiviral packaging IL231666B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306222 2011-09-26
PCT/IB2012/002363 WO2013046034A2 (en) 2011-09-26 2012-09-25 Use of non-subtype b gag proteins for lentiviral packaging

Publications (2)

Publication Number Publication Date
IL231666A0 IL231666A0 (en) 2014-05-28
IL231666B true IL231666B (en) 2018-03-29

Family

ID=47522726

Family Applications (1)

Application Number Title Priority Date Filing Date
IL231666A IL231666B (en) 2011-09-26 2014-03-23 Use of non-subtype b gag proteins for lentiviral packaging

Country Status (14)

Country Link
US (2) US9752160B2 (enExample)
EP (1) EP2761011B1 (enExample)
JP (3) JP6495653B2 (enExample)
KR (1) KR101811736B1 (enExample)
CN (2) CN107858375A (enExample)
AU (1) AU2012313960B2 (enExample)
BR (1) BR112014007027A2 (enExample)
CA (2) CA2959867C (enExample)
DK (1) DK2761011T3 (enExample)
ES (1) ES2683820T3 (enExample)
IL (1) IL231666B (enExample)
SG (1) SG11201400987QA (enExample)
WO (1) WO2013046034A2 (enExample)
ZA (1) ZA201401780B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913854A1 (en) 2013-06-03 2014-12-11 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
WO2015063706A1 (en) * 2013-10-31 2015-05-07 Theravectys Lentiviral vectors for expression of hiv-1 antigens
EP3009144A1 (en) * 2014-10-15 2016-04-20 Theravectys Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
WO2016120489A2 (en) * 2015-02-01 2016-08-04 Theravectys Lentiviral vectors for expression of mycobacterium tuberculosis antigens
US12084674B2 (en) * 2019-10-07 2024-09-10 University Of Utah Research Foundation Methods and compositions for a HIV based delivery system
US20250319173A1 (en) * 2021-03-12 2025-10-16 Institut Pasteur Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646606B1 (fr) * 1989-05-03 1994-06-17 Inst Nat Sante Rech Med Retrovirus hautement cytopathogenique hiv-ndk. fragment d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US7262049B2 (en) * 1999-03-16 2007-08-28 Dana-Farber Cancer Institute, Inc. Pseudotyped lentiviral vectors and uses thereof
EP1610816B1 (en) * 2003-03-28 2013-01-02 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mva virus expressing modified hiv envelope, gag, and pol genes
GB0318704D0 (en) * 2003-08-08 2003-09-10 Sirus Pharmaceuticals Ltd Chimaeric vector system
CA2539021A1 (en) 2003-09-15 2005-03-31 Chiron Corporation Combination approaches for generating immune responses
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
CN101353667B (zh) * 2008-08-15 2011-06-08 中国人民解放军军事医学科学院微生物流行病研究所 Hiv毒株耐药表型分析细胞模型及其专用假型慢病毒

Also Published As

Publication number Publication date
BR112014007027A2 (pt) 2017-04-11
CA2959867C (en) 2020-04-28
CN107858375A (zh) 2018-03-30
KR101811736B1 (ko) 2017-12-22
JP2017018132A (ja) 2017-01-26
ES2683820T3 (es) 2018-09-28
WO2013046034A3 (en) 2013-05-30
WO2013046034A2 (en) 2013-04-04
ZA201401780B (en) 2015-09-30
JP6495653B2 (ja) 2019-04-03
JP2014530000A (ja) 2014-11-17
CN104039968A (zh) 2014-09-10
EP2761011A2 (en) 2014-08-06
AU2012313960A1 (en) 2014-04-10
KR20140116053A (ko) 2014-10-01
US9752160B2 (en) 2017-09-05
AU2012313960B2 (en) 2016-05-12
HK1200870A1 (en) 2015-08-14
JP2018183165A (ja) 2018-11-22
CA2849652A1 (en) 2013-04-04
CA2849652C (en) 2017-11-21
NZ622860A (en) 2016-05-27
EP2761011B1 (en) 2018-05-23
CA2959867A1 (en) 2013-04-04
US20170362607A1 (en) 2017-12-21
IL231666A0 (en) 2014-05-28
US20140234908A1 (en) 2014-08-21
CN104039968B (zh) 2018-10-26
SG11201400987QA (en) 2014-07-30
DK2761011T3 (en) 2018-08-27

Similar Documents

Publication Publication Date Title
GB2492828B (en) Disposable container
GB201401337D0 (en) Disposable single use beverage package
PL2656827T3 (pl) Wyroby jednorazowego użytku zawierające równoległe rozszerzane elementy elastyczne
DK3061401T3 (da) Vævsbeholder
EP2678255A4 (en) FÖRDERBAND STERILIZATION
EP2773937A4 (en) INSPECTION OF A FLEXIBLE CONTAINER
GB201120373D0 (en) Name bubble handling
IL231666A0 (en) Use of non-subtype b gag proteins for lentiviral packaging
EP2764883A4 (en) PACKAGING FOR MEDICAL USE
BR112014001154A2 (pt) embalagem de alimento aperfeiçoada
PL2492216T3 (pl) Pojemnik na jajka
ZA201307227B (en) Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission
IL231494A0 (en) Lentiviral genome without chimeric integration as components against hiv-1
EP2758322A4 (en) DISPOSABLE PACKAGING AND SINGLE USE FOR BEVERAGE
PL2491874T3 (pl) Instrument chirurgiczny o usprawnionym sposobie posługiwania się nim
EP2724952A4 (en) DISPOSABLE PACKAGING
IL232926B (en) Mutated lentiviral env proteins and their use as drugs
GB2486529B (en) Dental instrument
GB201005057D0 (en) HIV-1 ENV-deactivating alpha-bodies
PL120050U1 (pl) Opakowanie jednorazowe do napoju alkoholowego
PL120049U1 (pl) Opakowanie jednorazowe do napoju alkoholowego
GB201113172D0 (en) Medical blister
GB201100346D0 (en) Packaging twelve
IL216464A0 (en) Hygaehis scehtep disposable can
EM18522030002S (sv) Pastaförpackningar; Förpackningar

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed